联合肽受体放射性核素治疗与强化化疗用于复发或难治性转移性儿童神经母细胞瘤的可行性与治疗潜力
该研究纳入14例病理确诊的儿童神经母细胞瘤患者,行68Ga-DOTATATE PET/CT评估,其中5例对131I-MIBG治疗难治或复发且高摄取者接受177Lu-DOTATATE联合化疗的PRRT,共19周期、66.4 GBq。2例初始完全缓解后数月复发,1例部分缓解,2例进展;中位总生存14.5个月(95%CI 8.9-20.1),毒性以1-2级血液学不良事件为主。
要点
- 68Ga-DOTATATE PET/CT在14例儿童NB中阳性10例(71.4%),阳性者中位检出病灶2个(范围1-13)。
- 5例接受177Lu-DOTATATE联合化疗,共19周期、66.4 GBq,2例初始CR后复发、1例PR、2例PD。
- 中位总生存14.5个月(95%CI 8.9-20.1),毒性主要为1-2级白细胞减少、贫血、血小板减少及1例1级血肌酐升高。
核心结论
- 177Lu-DOTATATE联合化疗在经包括131I-MIBG在内的常规治疗复发或难治的NB患儿中可能获得有价值的缓解、低毒性及令人鼓舞的生存。
- 68Ga-DOTATATE PET/CT在此类患者中检出效能较高,有望作为123I/131I-MIBG等常规影像的替代工具。
- 仍需进一步设计良好的试验验证。
研究设计与样本
- 单中心研究,纳入14例病理确诊的儿童NB患者行68Ga-DOTATATE PET/CT。
- 其中对131I-MIBG治疗难治或复发且68Ga-DOTATATE高摄取者行177Lu-DOTATATE联合化疗的PRRT。
- 采用CTCAE 4.03分级不良事件,Curie评分和SIOPEN评分半定量分析,Kaplan-Meier法估算总生存。
主要发现
- 14例患儿中男7例、女7例,中位年龄5.5岁(范围4-9岁);PET/CT阳性10/14(71.4%),阳性者中位病灶数2个(范围1-13)。
- 5例接受PRRT(男3例、女2例),共19周期、66.4 GBq 177Lu-DOTATATE。
- 5例中2例初始完全缓解后数月复发,1例部分缓解,2例进展。
- 中位总生存14.5个月(95%CI 8.9-20.1)。
- 毒性:白细胞减少1级4例、2级1例;贫血1级2例、2级2例;血小板减少1级2例、2级3例;血肌酐1级1例。
关键数值与推荐
- 治疗反应分为完全缓解、部分缓解、稳定疾病和进展性疾病。
- 不良事件按CTCAE 4.03分级。
- 采用Curie评分和SIOPEN评分对PRRT患者扫描进行半定量分析。
临床怎么用
- 对复发或难治性儿童NB可考虑68Ga-DOTATATE PET/CT评估生长抑素受体表达,阳性者或可筛选行177Lu-DOTATATE联合化疗。
- 治疗期间需按CTCAE监测血液学、肾及肝毒性。
- 该联合方案尚属探索性,需在规范试验框架下应用。
局限性
- 样本量小(14例,PRRT仅5例),非随机对照设计。
- 随访时间与生存分析基于小样本Kaplan-Meier估算。
- 作者指出需进一步设计良好的试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recent evidence has demonstrated high expression of somatostatin receptors in neuroblastoma (NB) cells. Because of this, we endeavored to evaluate the diagnostic performance and clinical efficacy of 68Ga-DOTATATE PET/CT and peptide receptor radionuclide therapy (PRRT) using 177Lu-DOTATATE combined with chemotherapy in pediatric NB patients. PATIENTS AND METHODS: In total, 14 pediatric patients with histopathologically confirmed NB underwent 68Ga-DOTATATE PET/CT. Among them, the patients who were refractory or relapsed after therapy with 131I-MIBG and had intensive uptake of 68Ga-DOTATATE were referred for PRRT using 177Lu-DOTATATE. Treatment response based on follow-up imaging was classified into complete response, partial response, stable disease, and progressive disease. After each cycle of PRRT, laboratory tests were performed for evaluation of hematological, renal, and hepatic toxicities. The CTCAE (Common Terminology Criteria for Adverse Events; version 4.03) was used for grading adverse event. Curie score and International Society of Pediatric Oncology Europe Neuroblastoma score were used for semiquantitative analysis of scans of patients who underwent PRRT. In addition, overall survival was calculated as the time interval between the date of the first cycle and the end of follow-up or death. RESULTS: Overall, 14 refractory NB children including 7 boys and 7 girls with a median age of 5.5 years (ranged from 4 to 9) underwent 68Ga-DOTATATE PET/CT. PET/CT was positive in 10/14 patients (71.4%), and the median number of detected lesions in positive patients was 2 (range, 1-13). Of 14 patients, 5 patients underwent PRRT, including 3 boys and 2 girls. A total of 19 PRRT cycles and 66.4 GBq 177Lu-DOTATATE were given. Among these 5 patients, 2 showed an initial complete response, which relapsed a few months later, 1 showed a partial response, and 2 showed progressive disease. According to the Kaplan-Meier test, the overall survival was estimated at 14.5 months (95% confidence interval, 8.9-20.1). In evaluation of PRRT-related toxicity according to the CTCAE, 4 patients showed grade 1, and 1 showed grade 2 leukopenia. Two patients showed grade 1, and 2 others showed grade 2 anemia. Two patients showed grade 1, and 3 patients showed grade 2 thrombocytopenia. Serum creatinine in 1 patient increased to grade 1. CONCLUSIONS: Combination of 177Lu-DOTATATE with chemotherapeutic agents might achieve worthwhile responses with low toxicity, encouraging survival in NB patients who have relapsed or are refractory to conventional therapy, including 131I-MIBG therapy. Imaging with 68Ga-DOTATATE PET/CT in such patients has a relatively high detection efficacy, demonstrating its potential use as an alternative imaging tool to conventional modalities such as 123I/131I-MIBG. However, further well-designed trials are highly warranted.
引用
- Fathpour G, Jafari E, Hashemi A, et al. Feasibility and Therapeutic Potential of Combined Peptide Receptor Radionuclide Therapy With Intensive Chemotherapy for Pediatric Patients With Relapsed or Refractory Metastatic Neuroblastoma. Clin Nucl Med. 2021. PMID: 33782280. doi:10.1097/RLU.0000000000003577
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。